34 results on '"Milana, M."'
Search Results
2. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance
3. Intermolecular interactions of cis-3-hexen-1-ol or 1-hexanol with n-hexane: Thermodynamic study, FT-IR analysis and quantum chemical calculations
4. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
5. Sarco-model, a novel score to better predict the risk of death in cirrhotic patients awaiting liver transplantation
6. Best methods for calculating interaction energies in 2-butene and butane systems
7. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
8. Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: results from a multicenter study
9. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?
10. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
11. Best methods for calculating interaction energies in 2-butene and butane systems
12. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
13. Natural HCV resistance is common in Italy and differently associated to genotypes
14. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease
15. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens
16. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?
17. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease
18. Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study
19. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus-infected patients treated with recommended regimens
20. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?
21. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting
22. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents
23. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients
24. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
25. Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting
26. Different Prevalence of HCV Resistance and HCV RNA Quantification Within Tumoral and Non Tumoral Liver Tissues in HCC/Transplanted Patients
27. Clinical and Functional Changes Associated with the Achievement of Sustained Response in HCV Genotype-1 Infected Liver Transplant Recipients: Does Sofosbuvir Differ from Peg-Interferon Therapy?
28. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C
29. Transarterial Chemoocclusion (Taco) With Degradable-Starch-Microsphere In Unresecable Hepatocellular Carcinoma: A Prospective Pilot-Study
30. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management
31. 166 HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION
32. P.11.22 HCV GENOME VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION: DOES THE VIRAL DIVERSITY PLAY A ROLE ON FIBROSIS PROGRESSION?
33. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation
34. Fluorogenic substrates for high-throughput measurements of endothelial lipase activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.